Acquired hemophilia a

Advances in Clinical Chemistry

Volumn 54, Issue , 2011, Pages 71-80

  Franchini, Massimo ^a   Lippi, Giuseppe ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Bleeding; Factor VIII autoantibodies; Inhibitors; RFVIIa; Rituximab

Indexed keywords

ANIMAL; BOOK; HEMOPHILIA A; HUMAN;

ANIMALS; HEMOPHILIA A; HUMANS;

EID: 79953873254     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-387025-4.00003-0     Document Type: Book

References (34)

1. Collins P.W., Hirsch S., Baglin T.P., Dolan G., Hanley J., Makris M., et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 2007, 109:1870-1877.
2. Collins P., Macartney N., Davies R., Lees S., Giddings J., Majer R. A population based, unselected, consecutive cohort of patients with acquired haemophilia A. Br. J. Haematol. 2004, 124:86-90.
3. Matsumoto T., Shima M., Fukuda K., Nogami K., Giddings J.C., Murakami T., et al. Immunological characterization of factor VIII autoantibodies in patients with acquired hemophilia A in the presence or absence of underlying disease. Thromb. Res. 2001, 104:381-388.
4. Prescott R., Nakai H., Saenko E.L., Scharrer I., Nilsson I.M., Humphries J.E., et al. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Blood 1997, 89:3663-3671.
5. Gawryl M.S., Hoyer L.W. Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood 1982, 60:1103-1109.
6. Green D., Blanc J., Foiles N. Spontaneous inhibitors of factor VIII: kinetics of inactivation of human and porcine factor VIII. J. Lab. Clin. Med. 1999, 133:260-264.
7. Shen B.W., Spiegel P.C., Chang C.H., Huh J.W., Lee J.S., Kim J., et al. The tertiary structure and domain organization of coagulation factor VIII. Blood 2008, 111:1240-1247.
8. Ngo J.C., Huang M., Roth D.A., Furie B.C., Furie B. Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa. Structure 2008, 16:597-606.
9. Wootla B., Nicoletti A., Patey N., Dimitrov J.D., Legendre C., Christophe O.D., et al. Hydrolysis of coagulation factors by circulating IgG is associated with a reduced risk for chronic allograft nephropathy in renal transplanted patients. J. Immunol. 2008, 180:8455-8460.
10. Wootla B., Mahendra A., Dimitrov J.D., Friboulet A., Borel-Derlon A., Rao D.N., et al. Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia. FEBS Lett. 2009, 583:2565-2572.
11. Jacquemin M.G., Desqueper B.G., Benhida A., Vander Elst L., Hoylaerts M.F., Bakkus M., et al. Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood 1998, 92:496-506.
12. Scandella D., Gilbert G.E., Shima M., Nakai H., Eagleson C., Felch M., et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 1995, 86:1811-1819.
13. Zhong D., Saenko E.L., Shima M., Felch M., Scandella D. Some human inhibitor antibodies interfere with factor VIII binding to factor IX. Blood 1998, 92:136-142.
14. Huth-Kühne A., Baudo F., Collins P., Ingerslev J., Kessler C.M., Lévesque H., et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009, 94:566-575.
15. Franchini M., Lippi G. Acquired factor VIII inhibitors. Blood 2008, 112:250-255.
16. Verbruggen B., Novakova I., Wessels H., Boezeman J., van den Berg M., Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb. Haemost. 1995, 73:247-251.
17. Baudo F., de Cataldo F. Acquired hemophilia: a critical bleeding syndrome. Haematologica 2004, 89:96-100.
18. Levesque H., Collins P., Baudo F., Huth-Kuhne A., Knoebl P., Marco P., et al. Acquired haemophilia: descriptive data of the European acquired haemophila registry (EACH 2). J. Thromb. Haemost. 2009, 7(Suppl. 2):PP-WE-604. (abstract).
19. Franchini M. Postpartum acquired factor VIII inhibitors. Am. J. Hematol. 2006, 81:768-773.
20. Franchini M., Capra F., Nicolini N., Veneri D., Manzato F., Baudo F., et al. Drug-induced anti-factor VIII antibodies: a systematic review. Med. Sci. Monit. 2007, 13:RA55-RA61.
21. Jansen N.W., Roosendaal G., Lafeber F.P. Understanding haemophilic arthropathy: an exploration of current open issues. Br. J. Haematol. 2008, 143:632-640.
22. Franchini M., Targher G., Montagnana M., Lippi G. Laboratory, clinical and therapeutic aspects of acquired hemophilia A. Clin. Chim. Acta 2008, 395:14-18.
23. Collins P.W. Treatment of acquired hemophilia A. J. Thromb. Haemost. 2007, 5:893-900.
24. Baudo F., Caimi T., de Cataldo F. Diagnosis and treatment of acquired hemophilia. Haemophilia 2010, 16:102-106.
25. Ichikawa S., Kohata K., Okitsu Y., Suzuki M., Nakajima S., Yamada M.F., et al. Acquired hemophilia A with sigmoid colon cancer: successful treatment with rituximab followed by sigmoidectomy. Int. J. Hematol. 2009, 90:33-36.
26. Shurafa M., Raman S., Wollner I. Disappearance of factor VIII antibody after removal of primary colon adenocarcinoma. Am. J. Hematol. 1995, 50:149-150.
27. Baudo F., Collins P., Huth-Kühne A., Knoebl P., Lévesque H., Pascual M., et al. Hemostatic therapy in acquired haemophilia: data from the European Acquired Haemophilia (EACH2) Registry. J. Thromb. Haemost. 2009, 7(Suppl. 2):OC-WE-058. (abstract).
28. Mannucci P.M., Peyvandi F. Autoimmune hemophilia at rescue. Haematologica 2009, 94:459-461.
29. Lambotte O., Dautremer J., Guillet B., Boutekedjiret T., Dreyfus M., Kotb R., et al. Acquired hemophilia in older people: a poor prognosis despite intensive care. J. Am. Geriatr. Soc. 2007, 55:1682-1685.
30. Girault S., Ly K., Jaccard A., Loustaud V., Turlure P., Julia A., et al. Prognosis of acquired hemophilia in older people. J. Am. Geriatr. Soc. 2008, 56:956-958.
31. Maloney D.G., Grillo-López A.J., White C.A., Bodkin D., Schilder R.J., Neidhart J.A., et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90:2188-2195.
32. Franchini M. Rituximab in the treatment of adult acquired hemophilia A: a systematic review. Crit. Rev. Oncol. Hematol. 2007, 63:47-52.
33. Sperr W.R., Lechner K., Pabinger I. Rituximab for the treatment of acquired antibodies to factor VIII. Haematologica 2007, 92:66-71.
34. Collins P., Baudo F., Huth-Kühne A., Knobl P., Levesque H., Marco P., et al. First line immunosuppressive treatment for acquired factor VIII antibodies: results of the European Acquired Haemophilia Registry (EACH2). J. Thromb. Haemost. 2009, 7(Suppl. 2):PP-MO-609. (abstract).